(New York Times) – A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

It’s easy to make a medical case for blockbuster weight loss drugs like Wegovy and Zepbound, which have been shown to prevent heart attacks and strokes and save lives. But for the employers and government programs being asked to pay for the medications, the financial case for them is less clear. Are the drugs’ benefits worth their enormous cost?

The answer right now is no, according to a new study published on Friday in the journal JAMA Health Forum, by researchers at the University of Chicago. (Read More)